Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program.

Low Urin Tract Symptoms · 2020 · PMC7004048 · PMID 31397969

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The remaining health‐related QoL parameters in the 50 and 25 μg desmopressin ODT groups showed an improvement compared with placebo, although the differences did not reach statistical significance (Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.